기업 프로필 · Industrials

FUJIFILM Holdings Corp

4901 · TSE
거래소
TSE
국가 / 지역
USA
상장일
1949년 5월 1일
직원 수
72,593
현재가
¥3,436
2026년 6월 28일 종가
적정 매수가
≤ ¥2,650
안전마진 진입가
베일리 성장 점수
46/100
다소 약함
내재가치 · 3단계 구간 현재가 ¥3,436 · 적정 내재가치 구간 내

종합 밸류에이션 구간 · 보수적 ¥2,450–¥2,650 / 적정 ¥3,250–¥4,150 / 낙관적 ¥5,150–¥5,450. ¥3,436 기준, 적정 내재가치 구간 내.

2026년 5월 20일 Update Confirmed

FUJIFILM Cellular Dynamics Launches New iPSC Manufacturing Facility in Madison

FUJIFILM Cellular Dynamics opened a new Madison iPSC headquarters and manufacturing facility, part of a $200 million U.S. investment.

Possible impact:May affect expectations for cell therapy manufacturing and life-sciences growth.

FUJIFILM CorporationView source
2026년 5월 12일 Earnings Confirmed

Fujifilm Announces Financial Results for the Fiscal Year Ended March 31, 2026

Fujifilm reported record FY2026 revenue, operating income and net income, and guided for further growth in FY2027.

Possible impact:May affect expectations for sustained growth in healthcare, semiconductor materials and imaging.

FUJIFILM Holdings CorporationView source
2026년 5월 8일 Regulatory Confirmed

Fujifilm Announces Approval of SAVYSCUS Injection in Japan

FUJIFILM Toyama Chemical received Japanese approval for SAVYSCUS Injection, a regenerative medical product for meniscal injury.

Possible impact:May affect expectations for regenerative medicine commercialization and healthcare differentiation.

FUJIFILM CorporationView source
2026년 4월 23일 Product Confirmed

Fujifilm Develops the World’s First Fluorine-Free Negative ArF Immersion Resist

Fujifilm developed a fluorine-free negative ArF immersion photoresist for advanced AI semiconductor nodes and began sampling.

Possible impact:May affect expectations for semiconductor materials competitiveness and PFAS-replacement demand.

FUJIFILM CorporationView source
2026년 3월 12일 Financing Confirmed

Fujifilm Invests in VALANX Biotech to Strengthen ADC CDMO Capabilities

Fujifilm invested in Austria’s VALANX Biotech to strengthen ADC CDMO technology and manufacturing capabilities.

Possible impact:May affect expectations for Bio CDMO positioning in the fast-growing ADC market.

FUJIFILM CorporationView source

Automatically summarized from public sources; for context only, not investment advice.

시가총액US$252.07억
매출 (TTM)US$3.36조
EBITDAUS$5225.81억
순이익률8.24%
ROE7.71%
PER (TTM)15.04
선행 PER13.21
PEG2.21
EPSUS$0.70
배당수익률2.22%
52주 범위US$8.82 – US$12.09

데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.

FUJIFILM Holdings Corporation provides products and services in the fields of healthcare, electronics, business innovation, and imaging in Japan, the Americas, Europe, Asia, and internationally. The Healthcare segment offers products and services, such as medical devices, biomedical contract development and manufacturing organization, pharmaceutical, regenerative medicine, and cosmetics and supplements in the areas of prevention, diagnosis, and treatment; equipment and materials for medical systems; drug discovery support, such as iPS cells; and cell culture media and reagents. Its Electronic segment provides display and touch panel, semiconductor and image sensors, and functional film materials; storage media and archiving services; semiconductor and display materials; industrial equipment; and fine chemicals. The Business Innovation segment offers office equipment, including multi-function devices and printers; problem-solving document services tailored to diverse business formats and roles, including system integration, cloud service, business process outsourcing, and others; equipment and materials for graphic communications; and inks and industrial inkjet printheads. Its Imaging segment provides color films, instant cameras, developing and printing systems, color papers, and photo printing services; TV and cinema lenses, surveillance cameras, industrial lenses for production line inspection, and projectors; instant photo systems; services for photofinishing; digital cameras; and optical devices. FUJIFILM Holdings Corporation was incorporated in 1934 and is headquartered in Minato, Japan.

연혁

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.

업계 내 위치

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.

이 종목에 대한 리포트가 아직 해당 언어로 없습니다.